UBS Group’s Endocyte, Inc. Common Stock ECYT Stock Holding History

UBS Group’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-500	Closed	-$3K	–	9054
2015 Q1	$3K	Sell	500 -10,000	-95%	-$57.7K	﹤0.01%	8370
2014 Q4	$66K	Buy	+10,500	New	+$64K	﹤0.01%	6155

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

UBS Group's ECYT Position: Q4 2018 in Review

UBS Group sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 18,392 shares — an estimated $327K sold.

UBS Group first reported a position in ECYT in Q4 2014 and held it in 16 quarters. The position peaked at $327K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

UBS Group reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
UBS Group sold 18,392 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $327K.
UBS Group first reported a position in Endocyte, Inc. Common Stock in Q4 2014 and held it in 16 quarters.
UBS Group's Endocyte, Inc. Common Stock position peaked at $327K in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on UBS Group's 13F filing for Q4 2018, filed 14 Feb 2019.